Hi, interesting read and I welcome some in depth discussion on...

Hi, interesting read and I welcome some in depth discussion on the company.

Just a quick reply. This was the base dosage of ppl-1 and it produced surprising results which were out of the ordinary and in my opinion are a pre-cursor to big things ahead. The chief investigator alluded to the surprise in the announcement. If we get similar results in canines then the sp will move massively I beleive. It just makes you wonder what impact the higher dosages will have.

This has increased the people watching the company and will most likely increase the trial sizes from now on. This is a huge plus for investors and will only add value in the not too distant future.

In regards to the cash position, we have received a large sum from our biggest customer of epichem. This was not reported in the quaterly but will be shown in the next.